Abstract
The monoclonal antibody OC125 (Centocor, Inc, Malvern, PA) was the basis for the first generation of one-step immunoradiometric assays (IRMA), used to detect the glycoprotein CA 125. Recently two-step IRMAs were developed: the CA 125 second-generation assays. In these new assays the CA 125 capture antibody is the M11 monoclonal antibody coated on a solid phase and the OC125 monoclonal antibody is used as tracer. We compared one first-generation radioassay and three second-generation assays (two radioassays and one ELISA) both analytically and clinically. The ELISA method showed the best within-assay precision and the best curve fitting characteristics. In the clinical comparison, none of the correlations between the first-generation and second-generation methods were really satisfactory; however, the cutoff level of 35 U/ml was confirmed. The four CA 125 assays do not yield equal results. As a consequence, the evolution of CA 125 serum concentrations during disease monitoring is not reliable when different determination methods are used consecutively.
Get full access to this article
View all access options for this article.